Ivabradine Grindeks (Ivabradine Hydrochloride)

Ivabradine is an If channel inhibitor used in cardiovascular conditions that require heart‑rate reduction.

• Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate.
• Heart failure with reduced ejection fraction (in combination with beta‑blockers): improves symptoms and lowers the risk of hospitalization.
• Patients intolerant to beta‑blockers: provides heart‑rate control without affecting myocardial contractility.

• Ivabradine selectively binds to the funny (If) current channels in the sino‑atrial node, inhibiting the inward sodium/potassium mixed current that drives spontaneous depolarisation. This action slows the pacemaker activity, producing a dose‑dependent reduction in heart rate while preserving myocardial contractility and blood pressure.

Ivabradine may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Bradycardia: heart rate falls below the desired range.
• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache.
• Dizziness.
• Fatigue.
• Blurred vision.

Serious or Rare Side Effects

• Symptomatic bradycardia requiring medical intervention.
• Atrial fibrillation or other supraventricular arrhythmias.
• Severe visual disturbances or persistent photopsia.
• Hypotension leading to syncope.
• Severe allergic reactions (e.g., rash, angioedema).
• Conduction abnormalities such as heart block.

Before initiating therapy, clinicians should evaluate cardiovascular status and monitor heart rate regularly.

• Baseline heart rate assessment: ensure resting rate is above 70 bpm before starting.
• Hepatic function: avoid or adjust dose in severe hepatic impairment.
• Conduction disorders: contraindicated in sick sinus syndrome or advanced AV block.
• Co‑administration with other bradycardic agents: use with caution when combined with beta‑blockers or digoxin.
• CYP3A4 inhibitors: avoid strong inhibitors that may increase plasma levels.
• Store at ambient temperature below 25 °C: keep in the original pack, protect from moisture.

Ivabradine may interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine concentrations.
• Concomitant use with other potent heart‑rate‑lowering drugs (e.g., beta‑blockers, digoxin) when excessive bradycardia is a risk.
• Drugs causing severe sinus node dysfunction.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment.

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Antihypertensive agents: monitor blood pressure for additive effects.